Noom research shows GLP-1 members who add a friend, bank steps, or log meals more frequently are more persistent with the medication.
Users who bank 20 times in the first 60 days after their first med log are 34% more likely to log medication in Week 4 vs. overall average and 75% more likely vs. users who bank <5 times
o By Week 8: the difference has grown to 41% vs. overall average and 93% vs. the <5 bank group
Users who log meals 20 times in the first 60 days after their first med log are 22% more likely to log medication in Week 4 vs. overall average and 72% more likely vs. users who log meals <5 times.
o By Week 8: the difference has grown to 27% vs. overall average and 94% vs. the <5 meal group.
Users who add at least one friend are +134% more likely to log medication in week 8 vs. users who didn’t add a friend.
Source: Compounded GLP-1 signups who logged medication for the first time between Jan 1-31
Users in the highest engagement quartile persisted on medication 2.2 times longer than those in the lowest quartile (6.2 vs. 2.8 months).
Data & methodology:
Medication program persistence and engagement: January 2026 analysis of 30,239 Noom GLP-1Rx Program members who started a GLP-1Rx plan between December 2024 and February 2025, evaluating program persistence by engagement quartile. Results based on users stratified into engagement quartiles during a trial period and then tracking the duration of their paid program membership (Months of persistence by engagement quartile: Q1 = 2.8 , Q4 = 6.2). Quartiles showed significantly different persistence, p = < .001.
Important note: These findings reflect observational analyses and report associations/correlations, not proof that engagement causes improved outcomes. Individual results vary. GLP-1 medications should be used under the guidance of a qualified healthcare provider.
Our research shows that GLP-1s may facilitate a shift in identity—81% of users reported a sense of “fresh start,” and 94% described becoming “more mindful eaters.”
Source: Keystone Habits Survey of 4,775 current and former GLP-1 users.
Survey Methodology:
Two surveys were fielded between February and March 2026. Survey 2 (S2): Surveyed 2,000 current and former GLP-1 users from the general population (average age 49; 42% male / 58% female). Topics included post-discontinuation outcomes, outcomes of companion program use, and habit sustenance.
Editorial standards
At Noom, we’re committed to providing health information that’s grounded in reliable science and expert review. Our content is created with the support of qualified professionals and based on well-established research from trusted medical and scientific organizations. Learn more about the experts behind our content on our Health Expert Team page.
